Briefcase

Plugging Recent Clinical Trial Data into Treatment Decisions: A Fundamental Formula

Launch Date
04/25/2022
Credit Amount
0.75 Hours
Credit Expires
04/25/2023

Faculty

Richard K. Bogan, MD, FCCP, FAASM
Associate Clinical Professor
University of South Carolina Medical School, Columbia, SC
Medical University of South Carolina, Charleston, SC
Principal, Bogan Sleep Consultants, LLC
Columbia, SC
Richard K. Bogan, MD, FCCP, FAASM

Dr. Bogan is the President of Bogan Sleep Consultants, LLC. He is also Associate Clinical Professor at the University of South Carolina School of Medicine and Associate Clinical Professor at the Medical University of South Carolina in Charleston, S.C.

Dr. Bogan received his bachelor’s degree in chemistry from Wofford College and his MD degree from the Medical University of South Carolina in Charleston. He served his internship and residency, as well as Chief Medical Resident, at the University of Alabama Hospital and Clinics in Birmingham. Thereafter, he completed a fellowship and assistant professorship in the Pulmonary Division of the Department of Medicine at the University of Alabama School of Medicine. He has been certified by the American boards of Sleep Medicine, Internal Medicine and Pulmonary Diseases.

Dr. Bogan has served as principal investigator on numerous clinical trials in the past and continues to do so now. He has a variety of publications and research interests that focus on topics such as narcolepsy, insomnia, sleep apnea, shift work sleep disorder, restless legs syndrome/periodic limb movement disorder, chronic fatigue/fibromyalgia and circadian rhythm abnormality.

Russell Rosenberg, PhD
Chief Science Officer and CEO, NeuroTrials Research, Inc., Atlanta, GA
Russell Rosenberg, PhD

Dr. Rosenberg is currently Chief Science Officer and CEO of NeuroTrials Research in Atlanta, GA. He obtained his doctorate in clinical and research psychology from The Ohio State University and received specialized training in sleep disorders medicine and research at Rush Presbyterian-St. Luke’s Medical center in Chicago. He has 33 years experience in clinical sleep medicine and research. He is a Board- Certified Sleep Specialist and Fellow of the American Academy of Sleep Medicine. He has made presentations on sleep disorders around the United States as well as in Asia and Europe. He has authored several book chapters and numerous journal articles on sleep disorders. His current research interests include treatments for disorders that cause excessive sleepiness.

Dr. Rosenberg is former Chair and spokesperson for the National Sleep Foundation (NSF) and has appeared frequently on local and national television news shows including the Today Show, Good Morning America, CNN, and MSNBC.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Additional Formats

Statement of Need

Stimulants are often used to manage persistent obstructive sleep apnea (OSA)-related excessive daytime sleepiness (EDS), yet sleepiness often persists in conjunction with safety concerns associated with the use of stimulants, particularly in patients with medical comorbidities. Nonstimulant therapies have emerged to offer sustained long-term efficacy with favorable safety and tolerability profiles. Yet, clinicians are often challenged in identifying best practices to apply clinical trial updates to practice, particularly in complex patients. Data continue to emerge on the safety and efficacy of nonstimulants in reducing the burden of OSA-related EDS. Therefore, clinicians need to be aware of these clinical updates in order to develop personalized treatment plans to optimize patient outcomes.

Join Dr. Bogan in this third and final installment of a case-based CMEO BriefCase series on OSA-related EDS as he translates data from recent clinical trials to optimize treatment decision-making.

 

Learning Objectives

At the end of this CME/CE activity, participants should be able to apply data from recent clinical trials to optimize treatment decision-making.

Financial Support

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in sleep, pulmonology, psychiatry, neurology, and/or primary care.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) 0.75

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 0.75

This application-based activity is approved for 0.75 contact hour (0.075 CEUs) of continuing pharmacy credit.
Activity UAN: 0376-0000-21-062-H02-P

PAs (AAPA) 0.75

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

Nurses (ANCC) 0.75

This activity is designated for 0.75 contact hour. Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

ABIM MOC 0.75

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Bogan reports the following financial relationships: Consultant: Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. Grants: Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. Speakers Bureau: Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.

Dr. Rosenberg reports the following financial relationships: Advisory Board: Harmony Biosciences, LLC. Research Support: Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. Speakers Bureau: Jazz Pharmaceuticals, Inc.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

  • Marlon (Tony) Graham, MD (peer reviewer)
  • Kashemi D. Rorie, PhD (planning committee)
  • Evan Luberger (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-062-H02-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

BC-064-042522-43

Related Activities

Sleep Disorders
01/18/2023

A New Dawn in the Management of Idiopathic Hypersomnia: An Adaptive Learning Approach to Diagnosis and Implementing Clinical Trial Updates

1.00 Hour
Begin Learn More
Sleep Disorders
05/09/2022

Navigating the Neurophysiology of Sleep and Cataplexy: The Significance of Select Neurotransmitters

1.00 Hours
Begin Learn More
Sleep Disorders
06/16/2020

Laying to Rest Challenges in Managing Excessive Daytime Sleepiness in Patients with Obstructive Sleep Apnea or Narcolepsy – An Augmented Reality Experience

0.00 Expired
Begin Learn More
Plugging Recent Clinical Trial Data into Treatment Decisions: A Fundamental Formula
Event Date: 04/25/2022
Begin